scispace - formally typeset
N

Nubia Muñoz

Researcher at International Agency for Research on Cancer

Publications -  342
Citations -  68481

Nubia Muñoz is an academic researcher from International Agency for Research on Cancer. The author has contributed to research in topics: Cervical cancer & Population. The author has an hindex of 110, co-authored 337 publications receiving 64948 citations. Previous affiliations of Nubia Muñoz include Peking Union Medical College & National and Kapodistrian University of Athens.

Papers
More filters
Journal ArticleDOI

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

TL;DR: The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
Journal ArticleDOI

Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer

TL;DR: In addition to HPV types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82Should be considered carcinogenic, or high-risk, types, and types 26, 53, and 66 should be considered probably carcinogenic.
Journal ArticleDOI

The causal relation between human papillomavirus and cervical cancer

TL;DR: It is the right time for medical societies and public health regulators to consider the causal role of human papillomavirus infections in cervical cancer and to define its preventive and clinical implications.
Journal ArticleDOI

Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective

TL;DR: The results confirm the role of genitalHPVs, which are transmitted sexually, as the central etiologic factor in cervical cancer worldwide and suggest that most genital HPVs are associated with cancer, at least occasionally.
Journal ArticleDOI

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

Silvia de Sanjosé, +62 more
- 01 Nov 2010 - 
TL;DR: HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines, according to this largest assessment of HPV genotypes to date.